Johnson & Johnson bought the Swiss pharmaceutical company Actelion for $ 30 billion

The American Corporation Johnson & Johnson buys Swiss pharmaceutical company Actelion Pharmaceuticals Ltd. The deal will amount to $ 30 billion. This is stated on the website of J&J.

Buying Actelion will allow J&J, which already is the world leader in production of medical supplies, add to the product range is a new category of drugs.

Actelion shareholders will receive $ 280 per share, payment will be made in cash.

Research unit Actelion will be allocated to independent R&D company NewCo, the shares of which will be posted on the exchange. Johnson & Johnson will retain a 16% stake in this company.

Actelion specializiruetsya in the production of drugs used in the treatment of pulmonary hypertension. The company was founded in 1997 by Jean-Paul Closeley, who now holds the position of General Director, his wife Martin closely and a group of researchers who previously worked in Roche Holding AG. The most famous drug Actelion — Tracleer, which is used to treat increased pressure in the blood vessels of the lungs.

The deal between Johnson & Johnson and Actelion will be the second largest in 2017 after the acquisition of tobacco company R. J. Reynolds of its British rival British American Tobacco for 49.4 billion USD.




Johnson & Johnson bought the Swiss pharmaceutical company Actelion for $ 30 billion 26.01.2017

0
Январь 26th, 2017 by
36 queries